Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for several cancer types compared to conventional cytotoxic therapies. However, the specific molecular and cellular mechanisms behind its efficacy are currently unclear. There is increasing evidence in murine models and i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Fernandez, Gonzalo, Chocarro, Luisa, Vera, Ruth, Kochan, Grazyna, Escors, David
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734243/
https://ncbi.nlm.nih.gov/pubmed/33329566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.586907
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars